Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022)

S Kurzel; A Blaudszun; L Stahl; R Herbst; F Kroschinsky; Josef Birkmann; A Hanel; K Schaefer-Eckart; G Ehninger; F Fiedler; M Bornhauser; S Fricke; M Hanel

doi:10.1007/s00432-022-04324-3

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022)

S Kurzel, A Blaudszun, L Stahl, R Herbst, F Kroschinsky, Josef Birkmann, A Hanel, K Schaefer-Eckart (Co-author), G Ehninger, F Fiedler, M Bornhauser, S Fricke, M Hanel

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Correction › peer-review

Original language	English
Journal	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
DOIs	https://doi.org/10.1007/s00432-022-04324-3
Publication status	Published - 2022

Access to Document

10.1007/s00432-022-04324-3

Cite this

Kurzel, S., Blaudszun, A., Stahl, L., Herbst, R., Kroschinsky, F., Birkmann, J., Hanel, A., Schaefer-Eckart, K., Ehninger, G., Fiedler, F., Bornhauser, M., Fricke, S., & Hanel, M. (2022). Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022). JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY https://doi.org/10.1007/s00432-022-04324-3

Kurzel, S ; Blaudszun, A ; Stahl, L et al. / Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022). In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 2022.

@article{ea8677b2721543e7a4f8258d1fceffed,

title = "Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022)",

author = "S Kurzel and A Blaudszun and L Stahl and R Herbst and F Kroschinsky and Josef Birkmann and A Hanel and K Schaefer-Eckart and G Ehninger and F Fiedler and M Bornhauser and S Fricke and M Hanel",

note = "Birkmann, Sch{\"a}fer-Eckart: Klinikum Nuernberg, Paracelsus Medical Private University, Medical Clinic 5, Nuremberg, Germany",

year = "2022",

doi = "10.1007/s00432-022-04324-3",

language = "English",

journal = "JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY ",

issn = "0171-5216",

publisher = "Springer Nature",

}

Kurzel, S, Blaudszun, A, Stahl, L, Herbst, R, Kroschinsky, F, Birkmann, J, Hanel, A, Schaefer-Eckart, K, Ehninger, G, Fiedler, F, Bornhauser, M, Fricke, S & Hanel, M 2022, 'Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022)', JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY https://doi.org/10.1007/s00432-022-04324-3

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022). / Kurzel, S; Blaudszun, A; Stahl, L et al.
In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , 2022.

Research output: Contribution to journal › Correction › peer-review

TY - JOUR

T1 - Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022)

AU - Kurzel, S

AU - Blaudszun, A

AU - Stahl, L

AU - Herbst, R

AU - Kroschinsky, F

AU - Birkmann, Josef

AU - Hanel, A

AU - Schaefer-Eckart, K

AU - Ehninger, G

AU - Fiedler, F

AU - Bornhauser, M

AU - Fricke, S

AU - Hanel, M

N1 - Birkmann, Schäfer-Eckart: Klinikum Nuernberg, Paracelsus Medical Private University, Medical Clinic 5, Nuremberg, Germany

PY - 2022

Y1 - 2022

U2 - 10.1007/s00432-022-04324-3

DO - 10.1007/s00432-022-04324-3

M3 - Correction

C2 - 36083312

SN - 0171-5216

JO - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

JF - JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

ER -

Kurzel S, Blaudszun A, Stahl L, Herbst R, Kroschinsky F, Birkmann J et al. Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (vol 148, pg 1171, 2022). JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY . 2022. doi: 10.1007/s00432-022-04324-3